Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar

U.S.-listed shares of Canadian drugmaker Theratechnologies TH.TO, THTX.O soar 52.6% to $2.35 premarket

US FDA has approved THTX's supplemental marketing application for Egrifta WR, a new tesamorelin formulation, to treat excess abdominal fat in HIV patients with a rare condition called lipodystrophy, co said on Tuesday

Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body

Egrifta WR is a daily injectable medication that only needs to be reconstituted weekly

Egrifta WR will replace the existing formulation, Egrifta SV, and will be available as a single-patient-use vial, co said

THTX gained ~15.8% in the last 12 months